Effects of biologics on vascular function and Atherosclerosis associated with Rheumatoid Arthritis

Research output: Chapter in Book/Report/Conference proceedingConference contribution

45 Citations (Scopus)

Abstract

Endothelial dysfunction and accelerated atherosclerosis lead to increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA). Sustained inflammation is a major risk factor. Apart from traditional vasculoprotective agents, biologics may also exert favorable effects on the vasculature. Indeed, tumor necrosis factor-α (TNF-α) inhibitors agents may transiently improve endothelial function. There are conflicting data regarding the effects of biologics on atherosclerosis and arterial stiffness. Infliximab stimulates the number and differentiation of endothelial progenitor cells that lead to vascular repair. There may be differences in the effects of TNF blockers on dyslipidemia, as long-term infliximab therapy may be proatherogenic, while some studies suggest that etanercept and adalimumab may exert beneficial effects on lipids. TNF blockers may decrease the incidence of cardiovascular events in RA. Preliminary data suggest that rituximab may also improve endothelial function and dyslipidemia. Further studies are needed to determine the net effects of biologics on the vasculature.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages814-821
Number of pages8
Volume1173
DOIs
Publication statusPublished - Sep 2009

Publication series

NameAnnals of the New York Academy of Sciences
Volume1173
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Dyslipidemias
Biological Products
Blood Vessels
Rheumatoid Arthritis
Atherosclerosis
Vascular Stiffness
Endothelial cells
Biological Factors
Repair
Tumor Necrosis Factor-alpha
Stiffness
Inflammation
Morbidity
Lipids
Mortality
Incidence
Infliximab
Therapeutics
Endothelial Progenitor Cells
Rituximab

Keywords

  • Arterial stiffness
  • Atherosclerosis
  • Carotid intima-media thickness
  • Endothelial dysfunction
  • Flow-mediated vasodilatation
  • Lipid profile
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effects of biologics on vascular function and Atherosclerosis associated with Rheumatoid Arthritis. / Kerekes, G.; Soltész, P.; Dér, H.; Veres, K.; Szabó, Z.; Végvári, A.; Shoenfeld, Yehuda; Szekanecz, Z.

Annals of the New York Academy of Sciences. Vol. 1173 2009. p. 814-821 (Annals of the New York Academy of Sciences; Vol. 1173).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Kerekes, G. ; Soltész, P. ; Dér, H. ; Veres, K. ; Szabó, Z. ; Végvári, A. ; Shoenfeld, Yehuda ; Szekanecz, Z. / Effects of biologics on vascular function and Atherosclerosis associated with Rheumatoid Arthritis. Annals of the New York Academy of Sciences. Vol. 1173 2009. pp. 814-821 (Annals of the New York Academy of Sciences).
@inproceedings{c8a52195851548d68715adfdb410f542,
title = "Effects of biologics on vascular function and Atherosclerosis associated with Rheumatoid Arthritis",
abstract = "Endothelial dysfunction and accelerated atherosclerosis lead to increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA). Sustained inflammation is a major risk factor. Apart from traditional vasculoprotective agents, biologics may also exert favorable effects on the vasculature. Indeed, tumor necrosis factor-α (TNF-α) inhibitors agents may transiently improve endothelial function. There are conflicting data regarding the effects of biologics on atherosclerosis and arterial stiffness. Infliximab stimulates the number and differentiation of endothelial progenitor cells that lead to vascular repair. There may be differences in the effects of TNF blockers on dyslipidemia, as long-term infliximab therapy may be proatherogenic, while some studies suggest that etanercept and adalimumab may exert beneficial effects on lipids. TNF blockers may decrease the incidence of cardiovascular events in RA. Preliminary data suggest that rituximab may also improve endothelial function and dyslipidemia. Further studies are needed to determine the net effects of biologics on the vasculature.",
keywords = "Arterial stiffness, Atherosclerosis, Carotid intima-media thickness, Endothelial dysfunction, Flow-mediated vasodilatation, Lipid profile, Rheumatoid arthritis",
author = "G. Kerekes and P. Solt{\'e}sz and H. D{\'e}r and K. Veres and Z. Szab{\'o} and A. V{\'e}gv{\'a}ri and Yehuda Shoenfeld and Z. Szekanecz",
year = "2009",
month = "9",
doi = "10.1111/j.1749-6632.2009.04645.x",
language = "English",
isbn = "9781573317627",
volume = "1173",
series = "Annals of the New York Academy of Sciences",
pages = "814--821",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Effects of biologics on vascular function and Atherosclerosis associated with Rheumatoid Arthritis

AU - Kerekes, G.

AU - Soltész, P.

AU - Dér, H.

AU - Veres, K.

AU - Szabó, Z.

AU - Végvári, A.

AU - Shoenfeld, Yehuda

AU - Szekanecz, Z.

PY - 2009/9

Y1 - 2009/9

N2 - Endothelial dysfunction and accelerated atherosclerosis lead to increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA). Sustained inflammation is a major risk factor. Apart from traditional vasculoprotective agents, biologics may also exert favorable effects on the vasculature. Indeed, tumor necrosis factor-α (TNF-α) inhibitors agents may transiently improve endothelial function. There are conflicting data regarding the effects of biologics on atherosclerosis and arterial stiffness. Infliximab stimulates the number and differentiation of endothelial progenitor cells that lead to vascular repair. There may be differences in the effects of TNF blockers on dyslipidemia, as long-term infliximab therapy may be proatherogenic, while some studies suggest that etanercept and adalimumab may exert beneficial effects on lipids. TNF blockers may decrease the incidence of cardiovascular events in RA. Preliminary data suggest that rituximab may also improve endothelial function and dyslipidemia. Further studies are needed to determine the net effects of biologics on the vasculature.

AB - Endothelial dysfunction and accelerated atherosclerosis lead to increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA). Sustained inflammation is a major risk factor. Apart from traditional vasculoprotective agents, biologics may also exert favorable effects on the vasculature. Indeed, tumor necrosis factor-α (TNF-α) inhibitors agents may transiently improve endothelial function. There are conflicting data regarding the effects of biologics on atherosclerosis and arterial stiffness. Infliximab stimulates the number and differentiation of endothelial progenitor cells that lead to vascular repair. There may be differences in the effects of TNF blockers on dyslipidemia, as long-term infliximab therapy may be proatherogenic, while some studies suggest that etanercept and adalimumab may exert beneficial effects on lipids. TNF blockers may decrease the incidence of cardiovascular events in RA. Preliminary data suggest that rituximab may also improve endothelial function and dyslipidemia. Further studies are needed to determine the net effects of biologics on the vasculature.

KW - Arterial stiffness

KW - Atherosclerosis

KW - Carotid intima-media thickness

KW - Endothelial dysfunction

KW - Flow-mediated vasodilatation

KW - Lipid profile

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=69949148371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949148371&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2009.04645.x

DO - 10.1111/j.1749-6632.2009.04645.x

M3 - Conference contribution

SN - 9781573317627

VL - 1173

T3 - Annals of the New York Academy of Sciences

SP - 814

EP - 821

BT - Annals of the New York Academy of Sciences

ER -